Fulvestrant formulation

Fulvestrant Formulierung

Formulation de fulvestrant

Abstract

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphmyl)nonyl]oestra-1,3,5(10)-thene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (5)

    Publication numberPublication dateAssigneeTitle
    EP-0310542-A1April 05, 1989Schering AktiengesellschaftComposés antigestagéniques et anti-oestrogéniques pour le traitement des tumeurs dépendant des hormones
    EP-0346014-A1December 13, 1989Zeneca LimitedProduit thérapeutique pour le traitement des états peri- ou postmènopausaux
    US-4388307-AJune 14, 1983Sandoz Ltd.Galenical compositions
    WO-9619997-A1July 04, 1996Schering AktiengesellschaftCompounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception
    WO-9721440-A1June 19, 1997Zeneca LimitedSolution contenant de l'ici 182,780 destinee a l'administration par voie orale

NO-Patent Citations (2)

    Title
    JOHN C. WATERTON; ET AL.: "A Case of Adenomyosis in a Pigtailed Monkey Diagnosed by Magnetic Resonance Imaging and treated with the Novel Pure Antiestrogen, ICI 182,780" LABORATORY ANIMAL SCIENCE, vol. 43, no. 3, 1993, pages 247-251, XP000998289
    RIFFKIN C ET AL: "CASTOR OIL AS A VEHICLE FOR PARENTERAL ADMINISTRATION OF STEROID HORMONES." JOURNAL OF PHARMACEUTICAL SCIENCES AUG 1964, vol. 53, August 1964 (1964-08), pages 891-895, XP009094139 ISSN: 0022-3549

Cited By (1)

    Publication numberPublication dateAssigneeTitle
    EP-2286818-A1February 23, 2011AstraZeneca ABFulvestrant formulation